ATE305296T1 - Zusammensetzungen und verfahren zur behandlung von abnormaler zellvermehrung - Google Patents

Zusammensetzungen und verfahren zur behandlung von abnormaler zellvermehrung

Info

Publication number
ATE305296T1
ATE305296T1 AT99933947T AT99933947T ATE305296T1 AT E305296 T1 ATE305296 T1 AT E305296T1 AT 99933947 T AT99933947 T AT 99933947T AT 99933947 T AT99933947 T AT 99933947T AT E305296 T1 ATE305296 T1 AT E305296T1
Authority
AT
Austria
Prior art keywords
methods
abnormal cell
compositions
vitamin
cell production
Prior art date
Application number
AT99933947T
Other languages
English (en)
Inventor
Pharma A S Leo
Original Assignee
Pharma A S Leo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma A S Leo filed Critical Pharma A S Leo
Application granted granted Critical
Publication of ATE305296T1 publication Critical patent/ATE305296T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
    • A61Q5/065—Preparations for temporary colouring the hair, e.g. direct dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99933947T 1998-07-16 1999-07-13 Zusammensetzungen und verfahren zur behandlung von abnormaler zellvermehrung ATE305296T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/116,632 US20010002396A1 (en) 1998-07-16 1998-07-16 Compositions and methods of treating skin conditions
PCT/US1999/015769 WO2000003700A1 (en) 1998-07-16 1999-07-13 Compositions and methods of treating abnormal cell proliferation

Publications (1)

Publication Number Publication Date
ATE305296T1 true ATE305296T1 (de) 2005-10-15

Family

ID=22368338

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99933947T ATE305296T1 (de) 1998-07-16 1999-07-13 Zusammensetzungen und verfahren zur behandlung von abnormaler zellvermehrung

Country Status (12)

Country Link
US (2) US20010002396A1 (de)
EP (1) EP1104294B8 (de)
JP (1) JP2002527356A (de)
AT (1) ATE305296T1 (de)
AU (1) AU4988999A (de)
CA (1) CA2337138A1 (de)
DE (1) DE69927507T2 (de)
DK (1) DK1104294T3 (de)
ES (1) ES2249900T3 (de)
MX (1) MXPA01000492A (de)
PT (1) PT1104294E (de)
WO (1) WO2000003700A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6538037B2 (en) 1991-01-08 2003-03-25 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US6503893B2 (en) 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
ES2368824T3 (es) * 1998-03-27 2011-11-22 Oregon Health & Science University Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos.
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
DE10010814A1 (de) * 2000-03-08 2001-09-13 Basf Ag Verwendung von 4-Oxoretinol und dessen Derivaten in kosmetischen Zubereitungen
EP2070911A2 (de) * 2000-07-18 2009-06-17 Bone Care International, Inc. Stabilisiertes 1-alpha-Hydroxy-Vitamin D
US6566399B2 (en) * 2000-08-03 2003-05-20 Byung-Moo Min Inhibitor of replicative senescence of human keratinocytes containing retinoic acid as active ingredients
AU2002363959B2 (en) * 2001-12-03 2007-12-13 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
US7273607B2 (en) * 2002-07-01 2007-09-25 Karl G. Schakel, legal representative Health enhancement method
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
AU2004210436A1 (en) * 2003-02-05 2004-08-19 Galderma Research & Development, S.N.C. Invert emulsion type composition containing at least one active agent sensitive to the presence of water, and its uses in cosmetics and in dermatology
AP2114A (en) * 2003-02-26 2010-03-04 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
US20060281813A1 (en) * 2003-06-05 2006-12-14 Charles Rubin Methods of treating hyperproliferative cell disorders
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
FR2862540B1 (fr) * 2003-11-21 2007-03-30 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
FR2871699A1 (fr) * 2004-06-17 2005-12-23 Galderma Sa Composition de type emulsion inverse contenant du calcitrol et du 17-propionate de clobetasol, et ses utilisations en cosmetiques et en dermatologie
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US20060073107A1 (en) * 2004-10-04 2006-04-06 Person John R Use of vitamin D3 (cholecalciferol) in sunscreens
US20100093674A1 (en) * 2005-08-04 2010-04-15 Person John R Skin cancer prevention method and product
US20060177390A1 (en) * 2005-02-08 2006-08-10 Person John R Skin cancer prevention method and product
CN101217868A (zh) * 2005-05-10 2008-07-09 德米普瑟尔有限公司 用于皮肤护理的组合物和方法
AU2006245283B2 (en) 2005-05-10 2012-11-01 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases
WO2006133828A1 (en) * 2005-06-17 2006-12-21 Dsm Ip Assets B.V. Novel use 25-hydroxycholecalciferol in combination with uv-b screening agents
FR2894465B1 (fr) * 2005-12-14 2010-09-10 Fabre Pierre Dermo Cosmetique Utilisation de composes polyinsatures en tant qu'agents blanchissants
US20080275128A1 (en) 2007-04-27 2008-11-06 Elliott C Lasser Compositions and methods for the treatment of inflammatory conditions
KR101880032B1 (ko) 2009-08-14 2018-07-20 베르그 엘엘씨 탈모증 치료용 비타민 ｄ3 및 이의 유사체들
US8747818B1 (en) 2011-02-07 2014-06-10 Dennis Gross Self-tanning compositions
US11103520B2 (en) * 2014-04-23 2021-08-31 The Regents Of The University Of California Analogs of N-acetlyglucosamine and uses thereof
AU2015269613A1 (en) * 2014-06-04 2016-12-22 Arbonne International, Llc Clear compositions and methods for the delivery of active ingredients for skin care
AU2015315047A1 (en) 2014-09-10 2017-04-27 Washington University Compositions and methods for treatment of pre-cancerous skin lesions
WO2019173533A1 (en) * 2018-03-07 2019-09-12 Athenex HK Innovative Limited Compositions and methods for treating hyperproliferative skin disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514672A (en) 1981-02-17 1996-05-07 Bazzano; Gail S. Use of retinoids and compositions containing same for hair growth
EP0133437A1 (de) * 1983-01-21 1985-02-27 Advanced Drug Technology Corporation Vitamin enthaltende hautpflegesalbe
DE3666587D1 (en) * 1985-08-02 1989-11-30 Leo Pharm Prod Ltd Novel vitamin d analogues
JPS6360910A (ja) 1986-09-01 1988-03-17 Shiseido Co Ltd 皮膚外用剤
US5763428A (en) * 1990-09-21 1998-06-09 Bone Care International, Inc. Methods of treating skin disorders with novel 1a-hydroxy vitamin D4 compounds and derivatives thereof
GB9109733D0 (en) * 1991-05-07 1991-06-26 Unilever Plc Cosmetic composition
TW272187B (de) 1992-05-20 1996-03-11 Hoffmann La Roche
US5547947A (en) * 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
FR2714595B1 (fr) 1993-12-30 1996-02-02 Oreal Emulsion eau dans huile contenant du rétinol, son utilisation et son conditionnement.
ATE228834T1 (de) 1994-09-30 2002-12-15 Oreal Verwendung von einem agonisten eines mit einem chloridkanal assozierten rezeptors zur behandlung von hautfalten
US5786391A (en) 1995-01-11 1998-07-28 Cornell Research Foundation, Inc. Regulating gene expression using retinoids with Ch2 OH or related groups at the side chain terminal position
FR2738745B1 (fr) 1995-09-15 1997-10-24 Cird Galderma Nouvelles compositions a base d'un melange synergetique entre au moins un ligand de vdr et un retinoide, et leurs utilisations

Also Published As

Publication number Publication date
EP1104294B1 (de) 2005-09-28
DE69927507D1 (de) 2006-02-09
EP1104294A1 (de) 2001-06-06
DE69927507T2 (de) 2006-03-23
CA2337138A1 (en) 2000-01-27
PT1104294E (pt) 2005-11-30
US20010002396A1 (en) 2001-05-31
EP1104294B8 (de) 2005-11-23
US6242435B1 (en) 2001-06-05
JP2002527356A (ja) 2002-08-27
WO2000003700A1 (en) 2000-01-27
EP1104294A4 (de) 2003-02-05
MXPA01000492A (es) 2002-11-29
ES2249900T3 (es) 2006-04-01
AU4988999A (en) 2000-02-07
DK1104294T3 (da) 2006-02-13

Similar Documents

Publication Publication Date Title
ATE305296T1 (de) Zusammensetzungen und verfahren zur behandlung von abnormaler zellvermehrung
DE59407237D1 (de) Nitrato-aminosäure-disulfide zur therapie von erkrankungen des herz-kreislauf-systems
MXPA05010682A (es) Compuestos novedosos.
WO2000059899A8 (fr) Nouveaux derives de l'acide lipoïque et les compositions pharmaceutiques les contenant
DE69823662D1 (de) 1,4,7,10-tetraazabicyclo(8.2.2)tetradecan-2-on, verfahren zu ihrer herstellung und ihrer verwendung für die herstellung von tetraazamacrocyclen
DE68907397D1 (de) Fluessige photopolymerisierbare zusammensetzung, viskoelastisches produkt, erhalten aus dieser zusammensetzung und verfahren zur herstellung dieses viskoelastischen produktes.
MXPA01006455A (es) Composiciones para el cuidado de la piel que contienen acido linoleico cis-9, trnas-11.
WO2002070729A3 (en) Improved skin substitutes and uses thereof
HRP990167B1 (en) Sulphinic acid derivatives, method for producing them, and their use
ATE411280T1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
AP9801269A0 (en) Prostaglandin agonists.
EP1098642A4 (de) Verfahren zur behandlung von zustanden moduliert durch lactosylceramiden
AU8647101A (en) Compounds having activity as inhibitors of cytochrome p450rai
DK0800503T3 (da) Hidtil ukendte trien-retinoidforbindelser og fremgangsmåder
IL153200A0 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING A gOBG3
PL336640A1 (en) Substituted 3,3-diamino-2- propenonitriles, their production and application
DE69927602D1 (de) Verfahren zur herstellung von vitaminpulvern
HK1040402A1 (zh) 使用乳粘素(lactadherin)或其變體的的方法及其組合物
AU2668800A (en) Mixture of plant-treatment agents and waxes, method for producing same and the use thereof
BG102553A (en) Thiol derivatives having metallopeptidase inhibitor activity
DE60231550D1 (de) Orale immunstimulierung von säugern, vögeln und reptilien durch (1-4)-verknüpfte beta-d-mannuronsäure
AU2003271811A8 (en) Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same
DE69513689D1 (de) Trizyclische retinoidverbindungen verfahren zu ihrer herstellung und verwendung
MY120085A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines.
ATE317021T1 (de) Antisense modulierung von lfa-3

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1104294

Country of ref document: EP

REN Ceased due to non-payment of the annual fee